Gilead to present promising data for Trodelvy in breast cancer at ESMO

FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD), a prominent biotechnology player with a market capitalization of $145.4 billion and impressive 78.5% gross profit margin, will present potentially practice-changing results for its cancer drug Trodelvy at the European Society for Medical Oncology (ESMO) 2025 Congress taking place October 17-21. According to InvestingPro analysis, the company appears undervalued based on its Fair Value calculations, suggesting potential upside for investors.

The company will showcase late-breaking data from the Phase 3 ASCENT-03 study evaluating Trodelvy (sacituzumab govitecan-hziy) as a first-line treatment for metastatic triple-negative breast cancer (TNBC) in patients who are not candidates for PD-1/PD-L1 inhibitors. According to the press release, the study met its primary endpoint, demonstrating a "highly statistically significant and clinically meaningful improvement" in progression-free survival compared to chemotherapy. With annual revenue of $28.86 billion and strong financial health metrics, Gilead is well-positioned to support the commercial expansion of Trodelvy.

Additionally, Gilead will present quality of life data from the ASCENT-04/KEYNOTE-D19 study, which evaluated Trodelvy plus Keytruda versus Keytruda and chemotherapy in first-line PD-L1-positive metastatic TNBC.

"With ASCENT-04 and now ASCENT-03, our data underscore the potential of Trodelvy to be a standard of care option for all first-line metastatic triple-negative breast cancer patients regardless of PD-L1 status," said Dietmar Berger, Chief Medical Officer at Gilead Sciences, in the press release.

The company will also present overall survival results from the Phase 2 EDGE-Gastric study, evaluating the combination of domvanalimab, zimberelimab and chemotherapy in advanced gastric or esophageal cancer. Preliminary data showed 50% of patients lived for more than two years, with a median overall survival of 26.7 months.

Trodelvy is currently approved in over 50 countries for second-line or later metastatic TNBC and in more than 40 countries for certain pre-treated HR+/HER2- metastatic breast cancer patients. Domvanalimab and zimberelimab remain investigational and have not received regulatory approval.

The information in this article is based on a press release statement from Gilead Sciences. For comprehensive analysis and additional insights about Gilead Sciences, including 8 more exclusive ProTips and detailed financial metrics, visit InvestingPro. The platform offers an extensive Pro Research Report for GILD, one of 1,400+ top US stocks, providing deep-dive analysis and actionable investment intelligence.

In other recent news, Gilead Sciences has made headlines with several key developments. The company has settled patent litigation with generic manufacturers, extending the market exclusivity of its HIV treatment, Biktarvy, from December 2033 to April 2036. This settlement involves agreements with Lupin Ltd., Cipla Ltd., and Laurus Labs Ltd. Additionally, RBC Capital has raised its price target for Gilead Sciences to $100, highlighting the potential of the new drug Yeztugo, which may exceed initial sales expectations. Bernstein has reiterated its Outperform rating on Gilead, with a price target of $135, following the company’s settlement news.

Needham also maintained its Buy rating and a $133 price target, emphasizing the potential of Gilead’s inflammation pipeline for long-term growth. However, there is some uncertainty as RBC analysts suggested that Gilead’s HIV medication Biktarvy might be a target for potential price cuts following recent comments by President Trump. These developments come amid a backdrop of strategic moves by Gilead to bolster its market position and future growth prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.